BEVERLY DICERBO: Open Payments
NPI 1720139033 · MARMORA, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$507 in 24 payments from 14 companies in 2025. Trend: 2023 $391 · 2024 $419 · 2025 $507
Food & beverage: $407Education: $100
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $152 |
| Novartis Pharmaceuticals Corporation | 4 | $70 |
| Dendreon Pharmaceuticals LLC | 3 | $60 |
| Incyte Corporation | 3 | $49 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| REVANCE THERAPEUTICS, INC. | 1 | $17 |
Products named: ERLEADA, KISQALI, PROVENGE, MONJUVI, KEYTRUDA, MONOFERRIC, VERZENIO, Lenvima.
Industry payments across NJ — which companies pay providers there.
